Articles
Rare is different: innovation happens at the margins

Rare is different: innovation happens at the margins

In the final post for 'Rare is different' Wendy White looks at the business environment for developing rare disorder therapies and addresses the role patient communities can play in getting drugs for rare diseases approved and to market. Due to the nature of the condition, a patient diagnosed with any one of the more than 7,000 rare diseases and disorders is part of...

Articles
Device ad-vice: dating vs. commitment: pharma vs. devices

Device ad-vice: dating vs. commitment: pharma vs. devices

In the first of a new series on medical device marketing Nancy Beesley highlights the key ways device marketing is different from pharma marketing. I started in medical advertising more than 20 years ago in a rising star agency that specialized in pharmaceutical marketing...

Articles
Device ad-vice: Best practices for handling a medical device recall

Device ad-vice: Best practices for handling a medical device...

In part 2 of the "Device ad-vice" series, Amy Smith offers advice for best practices on dealing with medical device recalls. Product recalls are a major headache for pharma, but device manufacturers can feel the pain, too. In the U.S., the FDA's 510(k) process for...

Sales & Marketing

Digital

Market Access

Editor's Picks

  1. FDA nominee Overton dodges questions on Trump influence
  2. Australia starts probe into AI infiltration of Medicare
  3. Lilly forges $3.35bn alliance with China's InnoCare
  4. Telix to buy radiopharma rival ITM for $1.65bn upfront
  5. Advocacy group pokes holes in Trump's MFN pricing claims

Newsletters and Deep Dive
digital magazine

Oncology

more

Patients

more

R&D

more